Postprandial Effects of Fresh Mango as a Table Sugar Replacement in High-Sugar Breakfasts.
Effects of Fresh Mango as a Table Sugar Replacement on Postprandial Intestinal Permeability and Inflammation Following a High-Sugar Breakfast.
1 other identifier
interventional
35
1 country
1
Brief Summary
Systemic inflammation and intestinal hyperpermeability (disruption of the gut barrier which allows nutrient molecules and bacteria to enter the bloodstream) are triggered by consumption of high-sugar meals and are linked to future development of cardiovascular disease (CVD). Previous research indicates that fresh mangos have properties that have positive effects on the intestinal barrier and local gut inflammation. The investigators want to understand if replacing table sugar (sucrose) with sugar from fresh mango (which also contains fiber and plant bioactives) will lead to decreased inflammatory and permeability biomarkers after eating a high-sugar breakfast. The investigators will compare the postprandial (post meal) levels of inflammatory (IL-6) and permeability (LPS, lipid binding protein (LBP), and soluble CD14) biomarkers in blood from participants who have consumed a meal sweetened with either sucrose or fresh mango.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Feb 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2026
CompletedFirst Submitted
Initial submission to the registry
June 10, 2026
CompletedFirst Posted
Study publicly available on registry
June 16, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2027
ExpectedJune 16, 2026
June 1, 2026
5 months
June 10, 2026
June 10, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
LPS
The investigators will measure LPS at baseline and 30-, 60-, 120-, and 180- minutes after each meal. These measurements will take place immediately and a complete dataset will be compiled upon study completion.
Through study completion, up to 1 year.
LPS Binding Protein
The investigators will measure LPS binding protein at baseline and 30-, 60-, 120-, and 180-minutes after each meal. These measurements will take place immediately and a complete dataset will be compiled upon study completion.
Through study completion, up to 1 year.
IL-6
The investigators will measure IL-6 at baseline and 30-, 60-, 120-, and 180-minutes after each meal. These measurements will take place immediately and a complete dataset will be compiled upon study completion.
Through study completion, up to 1 year.
Secondary Outcomes (3)
sCD14
Through study completion, up to 1 year.
Acceptability
Through study completion, up to 1 year.
Satiety
Through study completion, up to 1 year.
Other Outcomes (1)
Body Composition
Through study completion, up to 1 year.
Study Arms (2)
Cereal Consumption with Fresh Mango
EXPERIMENTALDuring the Cereal and Fresh Mango arm, participants will consume a bowl of corn flakes with 2% milk sweetened with fresh mango.
Cereal Consumption with Table Sugar
EXPERIMENTALDuring the Cereal and Table Sugar arm, participants will consume a bowl of corn flakes with 2% milk sweetened with table sugar.
Interventions
High-glycemic breakfast of 84 grams of corn flakes prepared with 355 mL of 2% milk and sweetened with 262 grams of fresh mango.
High-glycemic breakfast of 84 grams of corn flakes prepared with 355 mL of 2% milk and sweetened with 36 grams of table sugar.
Eligibility Criteria
You may qualify if:
- years.
- Body mass index between 18.5-35.0 kg/m2
- Not pregnant or expecting to become pregnant (females only)
- Not postmenopausal (females only).
- No known chronic medical conditions (e.g., type 2 diabetes, cardiovascular disease, inflammatory diseases, etc.)
- No history of using tobacco/illicit drugs
- No history of using glucose-lowering medications/supplements.
- No history of using prescribed anti-inflammatory medications
- Does not use over-the-counter anti-inflammatory medications ≥2x/week
- Does not have a pacemaker.
- No relevant food allergies/intolerances
- Able to lay supine for at least ten minutes.
You may not qualify if:
- Not between the ages of 18-45
- Body mass index \< 18.5 kg/m2 or \>35.0 kg/m2
- Pregnant (females only)
- Postmenopausal status (females only).
- Been diagnosed with a chronic medical conditions (e.g., type 2 diabetes, cardiovascular disease, inflammatory diseases, etc.)
- Uses tobacco products or any illicit drugs.
- Uses glucose-lowering drugs/supplements.
- Regularly takes anti-inflammatory drugs (more than 2x week).
- Have a pacemaker.
- Allergic to mango, wheat, gluten, and/or milk.
- Unable to lay in supine position in the dark for at least ten minutes.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ball State Universitylead
- National Mango Boardcollaborator
Study Sites (1)
Health Professions Building, Ball State University
Muncie, Indiana, 47306, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Bryant Keirns, PhD
Ball State University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 10, 2026
First Posted
June 16, 2026
Study Start
February 1, 2026
Primary Completion
July 1, 2026
Study Completion (Estimated)
January 1, 2027
Last Updated
June 16, 2026
Record last verified: 2026-06